« Previous | Next » | All Messages |  NPHC Message Board Home | recommend post |  Ignore Poster

NPHC News Nutra Pharma Chairman and CEO Outlines Business Strategy and Goals on CEOCast.com Interview

BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has today announced that CEOCast.com has published an interview by Nutra Pharma Chairman and CEO, Rik J. Deitsch.

“This CEOCast.com interview offers a perfect opportunity to present our current business strategy as well as our short-term and mid-term goals," explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “In addition, we believe that this interview provides background information that will be helpful for our shareholder conference call scheduled for Wednesday afternoon,” he added.

To access Mr. Deitsch's interview, go to http://www.ceocast.com and click on the "Interview Archives" link at the top of the page. You will be prompted to type in a company name or ticker symbol. At this point, type in Nutra Pharma or its ticker symbol, "NPHC," and you will be directed to the interview. If you do not have a free account, you will be required to register online to access the interview.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc., is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The CEOCast.com interview with Rik J. Deitsch should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.